Oncobiologics (NASDAQ:OTLK – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
Analyst Ratings
This is a summary of current recommendations and price targets for Oncobiologics and Entrada Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncobiologics | 1 | 2 | 2 | 0 | 2.20 |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Oncobiologics currently has a consensus target price of $5.20, suggesting a potential upside of 1,174.82%. Entrada Therapeutics has a consensus target price of $16.75, suggesting a potential upside of 233.00%. Given Oncobiologics’ higher probable upside, research analysts clearly believe Oncobiologics is more favorable than Entrada Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncobiologics | -$1.16 million | -85.35 | -$62.42 million | ($0.77) | -0.53 |
| Entrada Therapeutics | $25.42 million | 7.75 | -$143.75 million | ($3.84) | -1.31 |
Oncobiologics has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Oncobiologics and Entrada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncobiologics | N/A | N/A | -254.82% |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
Volatility & Risk
Oncobiologics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.
Institutional and Insider Ownership
11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Entrada Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.
About Oncobiologics
Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
